NASDAQ:MCRB

Seres Therapeutics Competitors

$21.39

+0.74 (+3.58 %)

(As of 04/15/2021 12:00 AM ET)

Add

Compare

Today's Range

$20.77

Now: $21.39▼

$22.13

50-Day Range

$17.66

MA: $20.12▼

$22.70

52-Week Range

$3.41

Now: $21.39▼

$38.50

Volume617,924 shs

Average Volume1.04 million shs

Market Capitalization$1.96 billion

P/E RatioN/A

Dividend YieldN/A

Beta4.07

Seres Therapeutics (NASDAQ:MCRB) Vs. RARE, ARWR, GWPH, ASND, TGTX, and IONS

Should you be buying MCRB stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Seres Therapeutics, including Ultragenyx Pharmaceutical (RARE), Arrowhead Pharmaceuticals (ARWR), GW Pharmaceuticals (GWPH), Ascendis Pharma A/S (ASND), TG Therapeutics (TGTX), and Ionis Pharmaceuticals (IONS).

Seres Therapeutics vs. Ultragenyx Pharmaceutical Stock

Seres Therapeutics (NASDAQ:MCRB) and Ultragenyx Pharmaceutical (NASDAQ:RARE) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, institutional ownership, analyst recommendations, dividends, earnings and profitability.

Risk and Volatility

Seres Therapeutics has a beta of 4.07, suggesting that its stock price is 307% more volatile than the S&P 500. Comparatively, Ultragenyx Pharmaceutical has a beta of 2.19, suggesting that its stock price is 119% more volatile than the S&P 500.

Valuation and Earnings

This table compares Seres Therapeutics and Ultragenyx Pharmaceutical's revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Seres Therapeutics	$34.51 million	56.74	$-70,280,000.00	($1.20)	-17.83
Ultragenyx Pharmaceutical	$103.71 million	70.18	$-402,730,000.00	($7.36)	-14.77

Seres Therapeutics has higher earnings, but lower revenue than Ultragenyx Pharmaceutical. Seres Therapeutics is trading at a lower price-to-earnings ratio than Ultragenyx Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent ratings for Seres Therapeutics and Ultragenyx Pharmaceutical, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Seres Therapeutics	0	1	6	0	2.86
Ultragenyx Pharmaceutical	0	6	8	0	2.57

Seres Therapeutics currently has a consensus price target of $38.1667, suggesting a potential upside of 78.43%. Ultragenyx Pharmaceutical has a consensus price target of $131.20, suggesting a potential upside of 20.73%. Given Seres Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Seres Therapeutics is more favorable than Ultragenyx Pharmaceutical.

Profitability

This table compares Seres Therapeutics and Ultragenyx Pharmaceutical's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Seres Therapeutics	-385.22%	-2,867.98%	-51.24%
Ultragenyx Pharmaceutical	-119.19%	-50.69%	-26.87%

Institutional & Insider Ownership

94.3% of Seres Therapeutics shares are held by institutional investors. 4.8% of Seres Therapeutics shares are held by insiders. Comparatively, 8.2% of Ultragenyx Pharmaceutical shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Seres Therapeutics vs. Arrowhead Pharmaceuticals Stock

Arrowhead Pharmaceuticals (NASDAQ:ARWR) and Seres Therapeutics (NASDAQ:MCRB) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, risk, dividends, valuation and earnings.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Arrowhead Pharmaceuticals and Seres Therapeutics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arrowhead Pharmaceuticals	0	2	10	0	2.83
Seres Therapeutics	0	1	6	0	2.86

Arrowhead Pharmaceuticals currently has a consensus price target of $85.3077, indicating a potential upside of 26.27%. Seres Therapeutics has a consensus price target of $38.1667, indicating a potential upside of 78.43%. Given Seres Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Seres Therapeutics is more favorable than Arrowhead Pharmaceuticals.

Risk and Volatility

Arrowhead Pharmaceuticals has a beta of 1.62, meaning that its share price is 62% more volatile than the S&P 500. Comparatively, Seres Therapeutics has a beta of 4.07, meaning that its share price is 307% more volatile than the S&P 500.

Profitability

This table compares Arrowhead Pharmaceuticals and Seres Therapeutics' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Arrowhead Pharmaceuticals	-96.09%	-17.37%	-15.19%
Seres Therapeutics	-385.22%	-2,867.98%	-51.24%

Earnings and Valuation

This table compares Arrowhead Pharmaceuticals and Seres Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arrowhead Pharmaceuticals	$87.99 million	79.69	$-84,550,000.00	($0.84)	-80.43
Seres Therapeutics	$34.51 million	56.74	$-70,280,000.00	($1.20)	-17.83

Seres Therapeutics has lower revenue, but higher earnings than Arrowhead Pharmaceuticals. Arrowhead Pharmaceuticals is trading at a lower price-to-earnings ratio than Seres Therapeutics, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

65.5% of Arrowhead Pharmaceuticals shares are owned by institutional investors. Comparatively, 94.3% of Seres Therapeutics shares are owned by institutional investors. 4.0% of Arrowhead Pharmaceuticals shares are owned by insiders. Comparatively, 4.8% of Seres Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Seres Therapeutics vs. GW Pharmaceuticals Stock

Seres Therapeutics (NASDAQ:MCRB) and GW Pharmaceuticals (NASDAQ:GWPH) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, dividends, profitability, analyst recommendations, valuation, institutional ownership and earnings.

Earnings & Valuation

This table compares Seres Therapeutics and GW Pharmaceuticals' revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Seres Therapeutics	$34.51 million	56.74	$-70,280,000.00	($1.20)	-17.83
GW Pharmaceuticals	$311.33 million	22.04	$-9,020,000.00	($0.24)	-912.08

GW Pharmaceuticals has higher revenue and earnings than Seres Therapeutics. GW Pharmaceuticals is trading at a lower price-to-earnings ratio than Seres Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current recommendations and price targets for Seres Therapeutics and GW Pharmaceuticals, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Seres Therapeutics	0	1	6	0	2.86
GW Pharmaceuticals	0	10	4	0	2.29

Seres Therapeutics presently has a consensus target price of $38.1667, indicating a potential upside of 78.43%. GW Pharmaceuticals has a consensus target price of $204.0909, indicating a potential downside of 6.69%. Given Seres Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Seres Therapeutics is more favorable than GW Pharmaceuticals.

Volatility and Risk

Seres Therapeutics has a beta of 4.07, suggesting that its share price is 307% more volatile than the S&P 500. Comparatively, GW Pharmaceuticals has a beta of 2.15, suggesting that its share price is 115% more volatile than the S&P 500.

Profitability

This table compares Seres Therapeutics and GW Pharmaceuticals' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Seres Therapeutics	-385.22%	-2,867.98%	-51.24%
GW Pharmaceuticals	-11.05%	-7.46%	-6.13%

Insider & Institutional Ownership

94.3% of Seres Therapeutics shares are owned by institutional investors. Comparatively, 81.0% of GW Pharmaceuticals shares are owned by institutional investors. 4.8% of Seres Therapeutics shares are owned by company insiders. Comparatively, 3.1% of GW Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

Seres Therapeutics beats GW Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

Seres Therapeutics vs. Ascendis Pharma A/S Stock

Ascendis Pharma A/S (NASDAQ:ASND) and Seres Therapeutics (NASDAQ:MCRB) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, risk, valuation, earnings, institutional ownership, analyst recommendations and dividends.

Valuation and Earnings

This table compares Ascendis Pharma A/S and Seres Therapeutics' revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ascendis Pharma A/S	$14.98 million	441.02	$-244,180,000.00	($5.25)	-23.41
Seres Therapeutics	$34.51 million	56.74	$-70,280,000.00	($1.20)	-17.83

Seres Therapeutics has higher revenue and earnings than Ascendis Pharma A/S. Ascendis Pharma A/S is trading at a lower price-to-earnings ratio than Seres Therapeutics, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Ascendis Pharma A/S has a beta of 0.77, meaning that its stock price is 23% less volatile than the S&P 500. Comparatively, Seres Therapeutics has a beta of 4.07, meaning that its stock price is 307% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Ascendis Pharma A/S and Seres Therapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ascendis Pharma A/S	0	1	11	0	2.92
Seres Therapeutics	0	1	6	0	2.86

Ascendis Pharma A/S presently has a consensus price target of $187.6667, indicating a potential upside of 52.69%. Seres Therapeutics has a consensus price target of $38.1667, indicating a potential upside of 78.43%. Given Seres Therapeutics' higher possible upside, analysts clearly believe Seres Therapeutics is more favorable than Ascendis Pharma A/S.

Institutional & Insider Ownership

94.3% of Seres Therapeutics shares are owned by institutional investors. 40.0% of Ascendis Pharma A/S shares are owned by insiders. Comparatively, 4.8% of Seres Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Profitability

This table compares Ascendis Pharma A/S and Seres Therapeutics' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Ascendis Pharma A/S	-4,042.79%	-55.72%	-49.42%
Seres Therapeutics	-385.22%	-2,867.98%	-51.24%

Seres Therapeutics vs. TG Therapeutics Stock

Seres Therapeutics (NASDAQ:MCRB) and TG Therapeutics (NASDAQ:TGTX) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their profitability, risk, institutional ownership, earnings, valuation, dividends and analyst recommendations.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Seres Therapeutics and TG Therapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Seres Therapeutics	0	1	6	0	2.86
TG Therapeutics	0	0	5	0	3.00

Seres Therapeutics currently has a consensus price target of $38.1667, indicating a potential upside of 78.43%. TG Therapeutics has a consensus price target of $64.00, indicating a potential upside of 39.37%. Given Seres Therapeutics' higher probable upside, equities research analysts plainly believe Seres Therapeutics is more favorable than TG Therapeutics.

Insider & Institutional Ownership

94.3% of Seres Therapeutics shares are owned by institutional investors. Comparatively, 65.7% of TG Therapeutics shares are owned by institutional investors. 4.8% of Seres Therapeutics shares are owned by insiders. Comparatively, 13.2% of TG Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Volatility and Risk

Seres Therapeutics has a beta of 4.07, indicating that its stock price is 307% more volatile than the S&P 500. Comparatively, TG Therapeutics has a beta of 2.28, indicating that its stock price is 128% more volatile than the S&P 500.

Profitability

This table compares Seres Therapeutics and TG Therapeutics' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Seres Therapeutics	-385.22%	-2,867.98%	-51.24%
TG Therapeutics	-151,798.69%	-223.96%	-108.08%

Valuation and Earnings

This table compares Seres Therapeutics and TG Therapeutics' gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Seres Therapeutics	$34.51 million	56.74	$-70,280,000.00	($1.20)	-17.83
TG Therapeutics	$150,000.00	43,038.06	$-172,870,000.00	($1.83)	-25.09

Seres Therapeutics has higher revenue and earnings than TG Therapeutics. TG Therapeutics is trading at a lower price-to-earnings ratio than Seres Therapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

Seres Therapeutics beats TG Therapeutics on 10 of the 14 factors compared between the two stocks.

Seres Therapeutics vs. Ionis Pharmaceuticals Stock

Ionis Pharmaceuticals (NASDAQ:IONS) and Seres Therapeutics (NASDAQ:MCRB) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, earnings, profitability, analyst recommendations, risk, institutional ownership and valuation.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Ionis Pharmaceuticals and Seres Therapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ionis Pharmaceuticals	2	7	6	0	2.27
Seres Therapeutics	0	1	6	0	2.86

Ionis Pharmaceuticals currently has a consensus target price of $57.9091, suggesting a potential upside of 41.14%. Seres Therapeutics has a consensus target price of $38.1667, suggesting a potential upside of 78.43%. Given Seres Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Seres Therapeutics is more favorable than Ionis Pharmaceuticals.

Volatility & Risk

Ionis Pharmaceuticals has a beta of 1.42, meaning that its stock price is 42% more volatile than the S&P 500. Comparatively, Seres Therapeutics has a beta of 4.07, meaning that its stock price is 307% more volatile than the S&P 500.

Earnings & Valuation

This table compares Ionis Pharmaceuticals and Seres Therapeutics' revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ionis Pharmaceuticals	$1.12 billion	5.15	$303.26 million	$2.08	19.73
Seres Therapeutics	$34.51 million	56.74	$-70,280,000.00	($1.20)	-17.83

Ionis Pharmaceuticals has higher revenue and earnings than Seres Therapeutics. Seres Therapeutics is trading at a lower price-to-earnings ratio than Ionis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Ionis Pharmaceuticals and Seres Therapeutics' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Ionis Pharmaceuticals	7.82%	6.57%	3.39%
Seres Therapeutics	-385.22%	-2,867.98%	-51.24%

Institutional & Insider Ownership

84.1% of Ionis Pharmaceuticals shares are held by institutional investors. Comparatively, 94.3% of Seres Therapeutics shares are held by institutional investors. 2.4% of Ionis Pharmaceuticals shares are held by insiders. Comparatively, 4.8% of Seres Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Ionis Pharmaceuticals beats Seres Therapeutics on 7 of the 13 factors compared between the two stocks.